Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

8.940 +0.130 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, contributory, and induced infringement claims. 
Via Benzinga
Topics Intellectual Property
1 Mid-Cap Stock on Our Buy List and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Peering Into Viatris's Recent Short Interest
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy. 
Via Benzinga
Top S&P500 movers in Friday's session
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Why Viatris (VTRS) Stock Is Falling Today
Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main... 
Via StockStory
What's going on in today's session: S&P500 gap up and gap down stocks
Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 S&P 500 Stocks in Hot Water
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Viatris Eye Drops Data Shows Promise For Blurred Near Vision
Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits. 
Via Benzinga
3 Unprofitable Stocks with Mounting Challenges
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
3 Healthcare Stocks with Questionable Fundamentals
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review
Medication company Viatris (NASDAQ:VTRS) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. Its non-GAAP EPS of $0.50 per share was 2.3%... 
Via StockStory
Topics Economy World Trade
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook. 
Via Benzinga
3 Stocks Under $10 Skating on Thin Ice
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
What's going on in today's session: S&P500 movers
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Top S&P500 movers in Thursday's session
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars
Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS guidance. 
Via Benzinga
Discover which S&P500 stocks are making waves on Thursday.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Viatris Q1 Earnings Exceed Wall Street Expectations, Company Raises Full-Year Profit Outlook: Retail’s Positive
The firm increased its full-year adjusted EPS guidance to $2.16 to $2.30 from its previous guidance of $2.12 to $2.26, including the impact of share repurchases. 
Via Stocktwits
Topics World Trade
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential. 
Via Benzinga
Topics ETFs Government
These S&P500 stocks that are showing activity before the opening bell on Thursday.
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday? 
Via Chartmill
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8%
Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance... 
Via StockStory
Top gainers and losers in the S&P500 index during Wednesday's after-hours session.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers. 
Via Chartmill
Wall Street Mixed Ahead Of Fed Meeting, Alphabet Sinks: What's Driving Markets Wednesday?
U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve’s upcoming policy decision, with Chair Jerome Powell set to speak at 2:30 p.m. ET. 
Via Benzinga
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.